Waylan Bessler

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

17h-index1.5kcitations302works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neurofibromatosis and Schwannoma Cases(274), Neuroblastoma Research and Treatments(202), Meningioma and schwannoma management(90), Nerve injury and regeneration(42), Sarcoma Diagnosis and Treatment(39)

Publications302 total

Table S3 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S6 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S12 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S9 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S7 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S4 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Table S4 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S10 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Table S6 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S13 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S11 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Table S1 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S8 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Figure S3 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

2025Open Access

Recombinant Human Neuregulin1‐β1 Significantly Reduces Schwannoma Growth in Mice

Annals of Neurology·2025Open Access

page 1 of 16Next →

Frequent Co-authors

D. Wade Clapp(35), Abbi E. Smith(33), Steven D. Rhodes(32), Steven P. Angus(26), Qingbo Lu(24), Dana K. Mitchell(24), Henry Mang(22), Li Jiang(22), George E. Sandusky(21), Xiaohong Li(21), Gary L. Johnson(17), Chi Zhang(15), David A. Ingram(13), Alyssa C. Flint(13), Brooke Rodriguez(13), Andi R. Masters(13), Pengtao Dang(13), Jenna Koenig(13), Weihua Shen(13), Jiangang Liu(13)